SB 5201 is scheduled for a public hearing in the Senate Committee for Labor & Commerce on Tuesday, February 18, 2025, at 10:30 AM. Please sign up to testify, submit written testimony, or state your position for the Senate record here:
“We should not force our service members or veterans to go down to Mexico to get this treatment.”— Congressman Dan Crenshaw, R-Texas
“From the opioid crisis to psilocybin’s potential with PTSD, it’s well past time we take drug use out of criminal consideration and into medical consideration.”— Rep. Alexandria Ocasio-Cortez, D-NY
“I try to tell people this isn’t partisan at all. Let’s take our labels away on this one. This is about humankind. This is about taking care of individuals. This is about saving lives. This is about giving people their lives back.”— Former Texas Governor Rick Perry
This bill creates a regulated framework for clinical and supervised access to psilocybin.
This legislation proposes a research study, managed by the University of Washington, to assess the effectiveness of ibogaine-assisted therapy to treat opioid use disorder.
Washington’s Clinical and Supervised Access to Psilocybin Bill.
A UW ibogaine research study to help people suffering from opioid use disorder.